Abstract
LT, LIGHT, and TNF are core family members of the TNFR superfamily of cytokines. LT and LIGHT, produced primarily by lymphocytes, interact with LTβR expressed by stromal and epithelial cells. Extensive studies over the last decade have revealed a critical role of LT-LTβR interactions for organogenesis and maintenance of the secondary lymphoid organs and in the generation of an efficient humoral immune response to various pathogens. LTβRs function beyond the lymphoid organs shows valuable potential yet remains largely undefined. Recent studies indicate that LTβR signaling is required for liver regeneration, hepatitis, and hepatic lipid metabolism. The balance of beneficial and detrimental effects of LTβR is critical for understanding the mechanisms of autoimmune disease and liver function and may open a new avenue for therapeutic intervention. This review will discuss recent advances in understanding LTβRs role in various human and murine disease models while focusing on its regulation of and implications in various liver related diseases.
Keywords: Lymphotoxin, lymphotoxin beta receptor, tumor necrosis factor, LIGHT, atherosclerosis, lipid metabolism, hepatic lipase
Current Molecular Medicine
Title: The Role of Lymphotoxin Receptor Signaling in Diseases
Volume: 7 Issue: 6
Author(s): Alexei V. Tumanov, Peter A. Christiansen and Yang-Xin Fu
Affiliation:
Keywords: Lymphotoxin, lymphotoxin beta receptor, tumor necrosis factor, LIGHT, atherosclerosis, lipid metabolism, hepatic lipase
Abstract: LT, LIGHT, and TNF are core family members of the TNFR superfamily of cytokines. LT and LIGHT, produced primarily by lymphocytes, interact with LTβR expressed by stromal and epithelial cells. Extensive studies over the last decade have revealed a critical role of LT-LTβR interactions for organogenesis and maintenance of the secondary lymphoid organs and in the generation of an efficient humoral immune response to various pathogens. LTβRs function beyond the lymphoid organs shows valuable potential yet remains largely undefined. Recent studies indicate that LTβR signaling is required for liver regeneration, hepatitis, and hepatic lipid metabolism. The balance of beneficial and detrimental effects of LTβR is critical for understanding the mechanisms of autoimmune disease and liver function and may open a new avenue for therapeutic intervention. This review will discuss recent advances in understanding LTβRs role in various human and murine disease models while focusing on its regulation of and implications in various liver related diseases.
Export Options
About this article
Cite this article as:
Tumanov V. Alexei, Christiansen A. Peter and Fu Yang-Xin, The Role of Lymphotoxin Receptor Signaling in Diseases, Current Molecular Medicine 2007; 7 (6) . https://dx.doi.org/10.2174/156652407781695701
DOI https://dx.doi.org/10.2174/156652407781695701 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A New Approach to the Inflammatory/Autoimmune Diseases
Recent Patents on Anti-Infective Drug Discovery T Cell-Activated Signaling Pathways and Locally Produced Cytokines as Potential Targets in Celiac Disease
Current Drug Targets Biological Activities, Mechanisms of Action and Biomedical Prospect of the Antitumor Ether Phospholipid ET-18-OCH3 (Edelfosine), A Proapoptotic Agent in Tumor Cells
Current Drug Metabolism Introduction from Editor-in-Chief
Current Rheumatology Reviews PKC-θ is a Drug Target for Prevention of T Cell-Mediated Autoimmunity and Allograft Rejection
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Metabolic Changes in Autoimmune Diseases
Current Drug Discovery Technologies The Use of Mesenchymal Stem Cells for the Treatment of Autoimmunity: From Animals Models to Human Disease
Current Drug Targets NF-κB in Type 1 Diabetes
Inflammation & Allergy - Drug Targets (Discontinued) Basement Membrane Peptides: Functional Considerations and Biomedical Applications in Autoimmunity
Current Medicinal Chemistry Regulation of Protective and Pathogenic Th17 Responses
Current Immunology Reviews (Discontinued) Chemokines and Autoimmune Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Neuropeptide - Adipose Tissue Communication and Intestinal Pathophysiology
Current Pharmaceutical Design Chinese Herbs as Immunomodulators and Potential Disease-Modifying Antirheumatic Drugs in Autoimmune Disorders
Current Drug Metabolism Targeting Toll-like Receptors in Autoimmunity
Current Drug Targets B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) The Role of Neutrophil Proteases in LPS-Induced Production of Regulatory Rheumatoid Factor that Suppresses Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis
Current Pharmaceutical Design Novel Molecular Targets for Systemic Lupus Erythematosus and Other Immune-Complex and T-Cell Mediated Autoimmune Diseases - Update
Medicinal Chemistry Reviews - Online (Discontinued) Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors
Current Medicinal Chemistry